Bernie PMP - Cytodyn VP Operations

CYDY Stock  USD 0.11  0.01  8.33%   

Insider

Bernie PMP is VP Operations of Cytodyn
Phone360 980 8524
Webhttps://www.cytodyn.com

Cytodyn Management Efficiency

The company has return on total asset (ROA) of (1.4819) % which means that it has lost $1.4819 on every $100 spent on assets. This is way below average. Cytodyn's management efficiency ratios could be used to measure how well Cytodyn manages its routine affairs as well as how well it operates its assets and liabilities.
Cytodyn currently holds 37.35 M in liabilities. Cytodyn has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cytodyn until it has trouble settling it off, either with new capital or with free cash flow. So, Cytodyn's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytodyn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytodyn to invest in growth at high rates of return. When we think about Cytodyn's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Katherine TaudvinScpharmaceuticals
N/A
Janetta TrochimiukPDS Biotechnology Corp
61
Robert WaltermireMadrigal Pharmaceuticals
60
Tod SmealCardiff Oncology
59
Rebecca MDMadrigal Pharmaceuticals
72
Nathalie RiebelPDS Biotechnology Corp
N/A
Timothy RolphAkero Therapeutics
70
Matthew CPAPDS Biotechnology Corp
55
James LevineCardiff Oncology
53
Lauren MDPDS Biotechnology Corp
64
Mark ErlanderCardiff Oncology
64
Remy SukhijaMadrigal Pharmaceuticals
52
William JDAkero Therapeutics
51
Vicki KelemenCardiff Oncology
N/A
Paul MDMadrigal Pharmaceuticals
81
Laxminarayan BhatReviva Pharmaceuticals Holdings
59
Narayan PrabhuReviva Pharmaceuticals Holdings
52
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people. Cytodyn [CYDY] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Cytodyn Leadership Team

Elected by the shareholders, the Cytodyn's board of directors comprises two types of representatives: Cytodyn inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytodyn. The board's role is to monitor Cytodyn's management team and ensure that shareholders' interests are well served. Cytodyn's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytodyn's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bernie PMP, VP Operations
George Bitar, Head Director
Denis Burger, Vice Chairman and Chief Science Officer
Antonio CPA, Treasurer CFO
Kush Dhody, VP Operations
Cyrus MBA, President
Cristina Leon, Investors

Cytodyn Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cytodyn a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cytodyn OTC Stock Analysis

When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.